Cargando…
Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results
BACKGROUND: Careful selection of hepatocellular carcinoma (HCC) patients prior to chemoembolization treatment is a daily reality, and is even more necessary with new available therapeutic options in HCC. AIM: To propose two new models to better stratify patients and maximize clinical benefit: “6 and...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223847/ https://www.ncbi.nlm.nih.gov/pubmed/34222423 http://dx.doi.org/10.12998/wjcc.v9.i18.4559 |
_version_ | 1783711776052871168 |
---|---|
author | Adhoute, Xavier Larrey, Edouard Anty, Rodolphe Chevallier, Patrick Penaranda, Guillaume Tran, Albert Bronowicki, Jean-Pierre Raoul, Jean-Luc Castellani, Paul Perrier, Hervé Bayle, Olivier Monnet, Olivier Pol, Bernard Bourliere, Marc |
author_facet | Adhoute, Xavier Larrey, Edouard Anty, Rodolphe Chevallier, Patrick Penaranda, Guillaume Tran, Albert Bronowicki, Jean-Pierre Raoul, Jean-Luc Castellani, Paul Perrier, Hervé Bayle, Olivier Monnet, Olivier Pol, Bernard Bourliere, Marc |
author_sort | Adhoute, Xavier |
collection | PubMed |
description | BACKGROUND: Careful selection of hepatocellular carcinoma (HCC) patients prior to chemoembolization treatment is a daily reality, and is even more necessary with new available therapeutic options in HCC. AIM: To propose two new models to better stratify patients and maximize clinical benefit: “6 and 12” and “pre/post-TACE-predict” (TACE, transarterial chemoembolization). METHODS: We evaluated and compared their performance in predicting overall survival with other systems {Barcelona Clinic Liver Cancer (BCLC), Albumin-Bilirubin (ALBI) and NIACE [Number of tumor(s), Infiltrative HCC, alpha-fetoprotein, Child-Pugh (CP), and performance status]} in two HCC French cohorts of different stages enrolled between 2010 and 2018. RESULTS: The cohorts included 324 patients classified as BCLC stages A/B (cohort 1) and 137 patients classified as BCLC stages B/C (cohort 2). The majority of the patients had cirrhosis with preserved liver function. “Pre-TACE-predict” and “6 and 12” models identified three distinct categories of patients exhibiting different prognosis in cohort 1. However, their prognostic value was no better than the BCLC system or NIACE score. Liver function based on CP and ALBI grades significantly impacted patient survival. Conversely, the “post-TACE-predict” model had a higher predictive value than other models. The stratification ability as well as predictive performance of these new models in an intermediate/advanced stage population was less efficient (cohort 2). CONCLUSION: The newly proposed “Pre-TACE-predict” and “6 and 12” models offer an interesting stratification into three categories in a recommended TACE population, as they identify poor candidates, those with partial control and durable response. The models' contribution was reduced in a population with advanced stage HCCs. |
format | Online Article Text |
id | pubmed-8223847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-82238472021-07-02 Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results Adhoute, Xavier Larrey, Edouard Anty, Rodolphe Chevallier, Patrick Penaranda, Guillaume Tran, Albert Bronowicki, Jean-Pierre Raoul, Jean-Luc Castellani, Paul Perrier, Hervé Bayle, Olivier Monnet, Olivier Pol, Bernard Bourliere, Marc World J Clin Cases Retrospective Cohort Study BACKGROUND: Careful selection of hepatocellular carcinoma (HCC) patients prior to chemoembolization treatment is a daily reality, and is even more necessary with new available therapeutic options in HCC. AIM: To propose two new models to better stratify patients and maximize clinical benefit: “6 and 12” and “pre/post-TACE-predict” (TACE, transarterial chemoembolization). METHODS: We evaluated and compared their performance in predicting overall survival with other systems {Barcelona Clinic Liver Cancer (BCLC), Albumin-Bilirubin (ALBI) and NIACE [Number of tumor(s), Infiltrative HCC, alpha-fetoprotein, Child-Pugh (CP), and performance status]} in two HCC French cohorts of different stages enrolled between 2010 and 2018. RESULTS: The cohorts included 324 patients classified as BCLC stages A/B (cohort 1) and 137 patients classified as BCLC stages B/C (cohort 2). The majority of the patients had cirrhosis with preserved liver function. “Pre-TACE-predict” and “6 and 12” models identified three distinct categories of patients exhibiting different prognosis in cohort 1. However, their prognostic value was no better than the BCLC system or NIACE score. Liver function based on CP and ALBI grades significantly impacted patient survival. Conversely, the “post-TACE-predict” model had a higher predictive value than other models. The stratification ability as well as predictive performance of these new models in an intermediate/advanced stage population was less efficient (cohort 2). CONCLUSION: The newly proposed “Pre-TACE-predict” and “6 and 12” models offer an interesting stratification into three categories in a recommended TACE population, as they identify poor candidates, those with partial control and durable response. The models' contribution was reduced in a population with advanced stage HCCs. Baishideng Publishing Group Inc 2021-06-26 2021-06-26 /pmc/articles/PMC8223847/ /pubmed/34222423 http://dx.doi.org/10.12998/wjcc.v9.i18.4559 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Cohort Study Adhoute, Xavier Larrey, Edouard Anty, Rodolphe Chevallier, Patrick Penaranda, Guillaume Tran, Albert Bronowicki, Jean-Pierre Raoul, Jean-Luc Castellani, Paul Perrier, Hervé Bayle, Olivier Monnet, Olivier Pol, Bernard Bourliere, Marc Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results |
title | Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results |
title_full | Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results |
title_fullStr | Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results |
title_full_unstemmed | Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results |
title_short | Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results |
title_sort | expected outcomes and patients’ selection before chemoembolization—“six-and-twelve or pre-tace-predict” scores may help clinicians: real-life french cohorts results |
topic | Retrospective Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223847/ https://www.ncbi.nlm.nih.gov/pubmed/34222423 http://dx.doi.org/10.12998/wjcc.v9.i18.4559 |
work_keys_str_mv | AT adhoutexavier expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT larreyedouard expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT antyrodolphe expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT chevallierpatrick expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT penarandaguillaume expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT tranalbert expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT bronowickijeanpierre expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT raouljeanluc expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT castellanipaul expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT perrierherve expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT bayleolivier expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT monnetolivier expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT polbernard expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults AT bourlieremarc expectedoutcomesandpatientsselectionbeforechemoembolizationsixandtwelveorpretacepredictscoresmayhelpcliniciansreallifefrenchcohortsresults |